Literature DB >> 16979425

Narcolepsy and the hypocretins.

Richard J Wurtman1.   

Abstract

Narcolepsy is a chronic neurologic disease characterized by excessive daytime sleepiness and one or more of three additional symptoms (cataplexy, or sudden loss of muscle tone; vivid hallucinations; and brief periods of total paralysis) related to the occurrence of rapid eye movement (REM) sleep at inappropriate times. The daytime sleepiness typically presents as a sudden overwhelming urge to sleep, followed by periods of sleep that last for seconds or minutes, or even longer. During daytime sleep episodes, patients may exhibit "automatic behavior," performing conventionalized functions (eg, taking notes), but not remembering having done so once they are awake. About 10% of narcoleptics are members of familial clusters; however, genetic factors alone are apparently insufficient to cause the disease, inasmuch as the most common genetic disorder, a mutation in chromosome 6 controlling the HLA antigen immune complex, although seen in 90% to 100% of patients, also occurs in as many as 50% of people without narcolepsy. A dog model of narcolepsy exhibits a mutation on chromosome 12 that disrupts the processing of the peptide neurotransmitter hypocretin. No such mutation characterizes human narcolepsy; however, cerebrospinal fluid (CSF) hypocretin levels are profoundly depressed in narcoleptic patients, and a specific reduction in hypocretin-containing neurons has been described. One hypothesis concerning the pathophysiology of narcolepsy proposes that the HLA subtype resulting from the mutation on chromosome 6 increases the susceptibility of hypocretin-containing brain neurons to immune attack. Because hypocretin may normally participate in the maintenance of wakefulness, the loss of neurons that release this peptide might allow REM sleep to occur at inappropriate times, ie, while the patient is awake, in contrast to its normal cyclic appearance after a period of slow-wave sleep. The cataplexy, hallucinations, and/or paralysis associated with REM episodes normally are unnoticed-or, at least, not remembered-when the transition to REM follows slow wave sleep, as is normally the case; however, they are remembered when, in people with narcolepsy, the REM episode starts during a period of wakefulness. The association of narcolepsy with a deficiency in a specific neurotransmitter, in this case, hypocretin, is reminiscent of the associations between Parkinson disease and dopamine, or early Alzheimer disease and acetylcholine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16979425     DOI: 10.1016/j.metabol.2006.07.011

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

Review 1.  Neuropsychological/-psychiatric deficits in immune-mediated neuropathies.

Authors:  Andrew Chan; Ralf Gold
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

Review 2.  Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment.

Authors:  D S Bond; J Roth; J M Nash; R R Wing
Journal:  Obes Rev       Date:  2011-05       Impact factor: 9.213

3.  OX2R activation induces PKC-mediated ERK and CREB phosphorylation.

Authors:  Yang Guo; Pingfu Feng
Journal:  Exp Cell Res       Date:  2012-05-29       Impact factor: 3.905

Review 4.  Genetics and epigenetics of circadian rhythms and their potential roles in neuropsychiatric disorders.

Authors:  Chunyu Liu; Michael Chung
Journal:  Neurosci Bull       Date:  2015-02-06       Impact factor: 5.203

5.  Medical exposures in youth and the frequency of narcolepsy with cataplexy: a population-based case-control study in genetically predisposed people.

Authors:  Thomas D Koepsell; William T Longstreth; Thanh G N Ton
Journal:  J Sleep Res       Date:  2009-08-31       Impact factor: 3.981

6.  Circadian rhythm disturbances in patients with Alzheimer's disease: a review.

Authors:  Dawit A Weldemichael; George T Grossberg
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

7.  Elevated peripheral visfatin levels in narcoleptic patients.

Authors:  Norbert Dahmen; Nina Manderscheid; Jana Helfrich; Petra B Musholt; Thomas Forst; Andreas Pfützner; Alice Engel
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.